ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | US

Overview

Corporate Details

ISIN(s):: US72703U1025 (+1 more)
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Roche Holding AG A global leader in pharmaceuticals and diagnostics, pioneering personalized healthcare solutions.	Switzerland	RO
ROCKET PHARMACEUTICALS, INC. Developing LV/AAV gene therapies for rare genetic bone marrow and cardiovascular diseases.	United States of America	RCKT
ROHTO PHARMACEUTICAL CO.,LTD. Manufactures OTC drugs, skincare, and cosmetics with a focus on eye and dermatological health.	Japan	4527
Roivant Sciences Ltd. Accelerates medicine and tech development by building agile, focused subsidiary companies.	United States of America	ROIV
RPbio Inc. A global CDMO specializing in soft capsules, pharmaceuticals, and health functional foods.	South Korea	314140
RTA LABORATUVARLARI BİYOLOJİK ÜRÜNLER İLAÇ VE MAKİNE SANAYİ TİCARET A.Ş. Develops and produces IVD kits and biological pharmaceuticals for the healthcare sector.	Türkiye	RTALB
RYTHM, Inc. Manages cannabis & hemp brands offering full-spectrum flower, vapes, and beverages.	United States of America	RYM
SAB Biotherapeutics, Inc. Develops human polyclonal antibodies for autoimmune disorders and infectious diseases.	United States of America	SABS
Sagimet Biosciences Inc. Clinical-stage biopharma developing FASN inhibitors for MASH, acne, and cancer.	United States of America	SGMT
SAMIL PHARMACEUTICAL CO.,LTD Develops & manufactures drugs for eye & liver diseases, with a broad portfolio & CDMO services.	South Korea	000520